Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and NASH Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PPARγ nuclear receptor drug discovery. Select your assay configuration below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Ligand Binding Domain) | PPAR Gamma LBD Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View PPAR Gamma Products |
| Antigen (Full Length) | PPAR Gamma (PPARG) Full-Length Protein Theoretical MW verified by mass spec. Native folding for co-factor recruitment assays. |
View PPAR Gamma Products |
| Mutant Variants | PPARG Pro12Ala (rs1805192) and other rare variant recombinant proteins Pharmacogenomic controls for assay validation. |
View PPAR Gamma Products |
| Subfamily Panel | PPAR Alpha / PPAR Delta LBD Proteins For selectivity counter-screening. Homolog panel strictly verified by mass spec. |
View PPAR Alpha Products / View PPARD Products |
| Heterodimer Partner | RXR Alpha (RXRA) Recombinant Protein Obligate heterodimer partner for functional reporter and SPR assays. |
View RXR Alpha Products |
| Gene Delivery | PPAR Gamma Promise-ORF Lentivirus Full-length ORF for stable cell line construction (reporter assays). |
View PPAR Gamma Products |
| Benchmark Antibody | Anti-PPARG Monoclonal Antibody (Research Grade) Recombinant positive control for ChIP, WB, and ICC validation. |
View PPAR Gamma Products |
| Validator | PPAR Gamma siRNA Set For knockdown verification and specificity controls in cellular assays. |
View PPAR Gamma Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (PPARα/γ/δ discrimination) | Human/Mouse ortholog LBD proteins available with >95% purity; Sequence Verified for accurate SAR profiling across subfamily members |
| Coactivator Recruitment Conformation (SPPARM vs. full agonist) | Full-length PPARγ with intact AF-2 domain for NCoR/SMRT co-repressor recruitment studies; LBD proteins suitable for TR-FRET/AlphaScreen |
| Pharmacogenomic Controls | PPARG Pro12Ala mutant and rare variant recombinant proteins included as assay controls |
| Species Translation (Rodent to Human) | Human/Mouse/Cyno PPARγ LBD proteins with identical QC standards for cross-species potency correlation |
| False Positives in Cell-Based Assays | PPARG siRNA included for target knockdown validation in PPRE reporter and adipogenesis assays |
Live PPAR Gamma R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The PPARγ therapeutic landscape is experiencing a strategic pivot from traditional full agonists (thiazolidinediones, TZDs) toward selective PPARγ modulators (SPPARMs), partial agonists, and tissue-specific dual agonists. Following safety constraints imposed on first-generation insulin sensitizers (cardiovascular risk, adipogenesis, fluid retention), the industry has shifted toward molecules that retain insulin-sensitizing efficacy while minimizing adverse effects. The current pipeline emphasizes NASH (non-alcoholic steatohepatitis), PBC (primary biliary cholangitis), and metabolic syndrome, with diabetes moving toward combination therapies (e.g., with GLP-1R agonists). As first-generation molecules face generic competition, the next wave focuses on PPARα/γ dual agonists and pan-PPAR modulators (PPARα/γ/δ) that address dyslipidemia and fibrosis holistically. Emerging modalities include PROTAC-based PPARγ degraders for cancer indications (liposarcoma).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| SPPARMs (Selective Modulators) / Partial Agonists | Inventiva, Lilly, Novo Nordisk, Chugai, Kaken | T2D, NASH | Coactivator recruitment assay using high-purity PPARG LBD protein to distinguish partial vs. full agonism |
| Dual PPARα/γ Agonists | Saroglitazar developers, Takeda, Genfit | NASH, Dyslipidemia | Subfamily selectivity panel (PPARα/γ LBD proteins) to confirm balanced activation |
| Pan-PPAR Agonists | Inventiva (Lanifibranor), Elafibranor derivatives | NASH, PBC, Rare Fibrotic Diseases | Triple ortholog protein panel (Human/Mouse/Cyno) for species translation and full PPAR panel counter-screen |
| Antagonists / Inverse Agonists / PROTACs | Academic consortia, biotechs | Cancer (Liposarcoma) | Co-repressor recruitment assays using full-length PPARγ; protein conformational stability for ternary complex formation |
| Non-TZD Small Molecules | Several Biotechs | Metabolic Disease, Ulcerative Colitis | Thermal shift and direct binding assays with structurally verified PPARG LBD mutants |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Modulation Mode: SPPARMs induce partial agonism, avoiding full activation of adipogenic and fluid retention pathways. Assays must differentiate co-activator vs. co-repressor recruitment balance.
- Conformational Control: Ligand binding induces specific conformational changes that dictate the recruitment of transcriptional coregulators (e.g., PGC-1α, NCoR). TR-FRET/AlphaScreen with peptide panels can profile these interactions.
- Selectivity Window: For dual/pan agonists, precise ratio of PPARα/γ/δ activation is critical. Counter-screening with PPARA and PPARD LBD proteins is mandatory.
- Mutant Variants: Common polymorphisms like Pro12Ala (rs1805192) and rare variants (e.g., rs1800571) affect drug response and should be included as pharmacogenomic controls.
Recommended Assay Workflow
- Primary binding: Direct binding assay (SPR/ITC) using PPARG LBD protein.
- Selectivity panel: Parallel profiling against PPARA/PPARD LBD proteins.
- Functional activation: Co-activator recruitment TR-FRET assay with full-length PPARG or LBD.
- Cellular validation: PPRE reporter cell line with PPARG lentivirus; confirm specificity with PPARG siRNA.
- Pharmacogenetic control: Test against Pro12Ala and other variant proteins to anticipate population variability.
Related Target Recommendations for Cross-Sell
- PPARA / PPARD: Essential counter-screening targets for any PPARG modulator program. Dual agonist development requires precise selectivity profiling.
- RXRA (Retinoid X Receptor Alpha): Obligate heterodimer partner of PPARG. Functional assays require RXRα co-protein to achieve physiological conformation.
- GLP-1R: Growing combination therapy trend in metabolic disease (PPARG + GLP-1R agonist). Overlapping customer base in metabolic disease research.
All reagent data sourced from TarMart with >95% purity, endotoxin <1 EU/µg, and sequence verification by mass spec.